Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roivant Sciences Ltd
(NQ:
ROIV
)
11.29
-0.07 (-0.66%)
Streaming Delayed Price
Updated: 11:49 AM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,699,649
Open
11.37
Bid (Size)
11.29 (57)
Ask (Size)
11.30 (31)
Prev. Close
11.37
Today's Range
11.18 - 11.41
52wk Range
8.245 - 13.05
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
September 18, 2024
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2...
Via
Benzinga
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
September 18, 2024
From
Roivant Sciences
Via
GlobeNewswire
Performance
YTD
-0.48%
-0.48%
1 Month
-4.04%
-4.04%
3 Month
+6.96%
+6.96%
6 Month
+3.43%
+3.43%
1 Year
+7.42%
+7.42%
More News
Read More
4 Analysts Assess Roivant Sciences: What You Need To Know
September 11, 2024
Via
Benzinga
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
September 10, 2024
Via
Benzinga
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
September 10, 2024
From
Roivant Sciences
Via
GlobeNewswire
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
June 18, 2024
Via
Benzinga
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
September 10, 2024
From
Roivant Sciences
Via
GlobeNewswire
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
September 09, 2024
Via
Benzinga
Roivant Provides Update on Graves’ Disease Development Program
September 09, 2024
From
Roivant Sciences
Via
GlobeNewswire
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
May 31, 2024
Via
Benzinga
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
April 22, 2024
Via
Benzinga
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
August 29, 2024
Via
Investor's Business Daily
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
August 08, 2024
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
July 25, 2024
From
Roivant Sciences
Via
GlobeNewswire
ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024
May 30, 2024
Via
InvestorPlace
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
May 30, 2024
From
Roivant Sciences
Via
GlobeNewswire
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
May 22, 2024
Via
Benzinga
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
May 16, 2024
From
Roivant Sciences
Via
GlobeNewswire
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
May 07, 2024
Via
InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
May 01, 2024
Via
InvestorPlace
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
April 02, 2024
Via
Benzinga
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
April 02, 2024
Via
Investor's Business Daily
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
April 02, 2024
From
Roivant Sciences
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
March 29, 2024
Via
Benzinga
Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase
March 27, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.